Evaluation of INFγ in serum of Crohn’s patients by using ELISA technique
DOI:
https://doi.org/10.32792/utq/utjsci/v12i2.1388Abstract
Crohn’s disease, a chronic inflammatory bowel disorder that can cause gradual intestinal damage and an impairment. CD can affect people of all ages, from children to the elderly, and can causes a considerable morbidity and reduce the quality of life. The main aim of this study was to explore the serum level and evaluate the predictive role of immunological parameters of Interferon gamma (INF-γ) for the detection of an active disease in Crohn’s patient. The current investigation, 70 blood samples acquired from Crohn's disease patients and 70 apparently healthy individuals were used. A sandwich ELISA kit (No: E-EL-H0108) U.S.A. was used to determine serum levels of INF-γ that contribute to disease progression. A total of 140 samples (70 cases and 70 controls) were collected in a 1:1 ratio, with each participant was screened base on inclusion and exclusion criteria. This study encourages employing INF-γ as a predictive biomarker for Crohn’s disease.
Received: 2025-05-06
Revised: 2025-06-17
Accepted: 2025-07-17
References
[1]M. Dolinger, J. Torres, and S. Vermeire, “Crohn’s disease,” Lancet (London, England), vol. 403, no. 10432, pp. S0140-6736(23)025862, Mar. 2024, doi: https://doi.org/10.1016/S0140-6736(23)02586-2.
[2]Y. Yuan, M. Fu, N. Li, and M. Ye, “Identification of immune infiltration and cuproptosis-related subgroups in Crohn’s disease,” Frontiers in Immunology, vol. 13, no. 13:1074271, Nov. 2022, doi: https://doi.org/10.3389/fimmu.2022.1074271.
[3] J. Kershaw et al., “Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn’s Disease in the United States and Europe,” Crohn’s & Colitis 360, vol. 7, no. 1, Nov. 2024, doi: https://doi.org/10.1093/crocol/otae074.
[4] A. L. Lightner et al., “The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn’s Disease,” 2020; 63: 1028–1052, vol. 63, no. 8, pp. 1028–1052, Aug. 2020, doi: https://doi.org/10.1097/dcr.0000000000001716.
[5]C. Hu, S. Liao, L. Lv, C. Li, and Z. Mei, “Intestinal Immune Imbalance is an Alarm in the Development of IBD,” Mediators of Inflammation, vol. 2023, no. 1073984, 17 page, pp. 1–17, Jul. 2023, doi: https://doi.org/10.1155/2023/1073984.
[6]S. Jarmakiewicz-Czaja, M. Zielińska, A. Sokal, and R. Filip, “Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update,” Genes, vol. 13, no. 12, p. 2388, Dec. 2022, doi: https://doi.org/10.3390/genes13122388.
[7] L. Petagna et al., “Pathophysiology of Crohn’s disease inflammation and recurrence,” Biology Direct, vol. 15, no. 1, Nov. 2020, doi: https://doi.org/10.1186/s13062-020-00280-5
[8] R. Panaccione, “What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn’s disease?,” Journal of the Canadian Association of Gastroenterology, vol. 8, no. Supplement_2, pp. S1–S5, Feb. 2025, doi: https://doi.org/10.1093/jcag/gwae053.
[9] N. Li and R.-H. Shi, “Updated review on immune factors in pathogenesis of Crohn’s disease,” World Journal of Gastroenterology, vol. 24, no. 1, pp. 15–22, Jan. 2018, doi: https://doi.org/10.3748/wjg.v24.i1.15.
[10] H. Ding, G. Wang, Z. Yu, H. Sun, and L. Wang, “Role of interferon-gamma (IFN-γ) and IFN-γ receptor 1/2 (IFNγR1/2) in regulation of immunity, infection, and cancer development: IFN-γ-dependent or independent pathway,” Biomedicine & Pharmacotherapy, vol. 155, no. https://doi.org/10.1016/j.biopha.2022.113683, p. 113683, Nov. 2022, doi: https://doi.org/10.1016/j.biopha.2022.113683.
[11] I. Stolzer, A. Dressel, M. T. Chiriac, M. F. Neurath, and C. Günther, “An IFN-STAT Axis Augments Tissue Damage and Inflammation in a Mouse Model of Crohn’s Disease,” Frontiers in Medicine, vol. 8, no. Front. Med. 8:644244., May 2021, doi: https://doi.org/10.3389/fmed.2021.644244.
[12] P. Xu, M. Elizalde, A. Masclee, M. Pierik, and D. Jonkers, “Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn’s disease,” Journal of Molecular Medicine, vol. 99, no. 6, pp. 805–815, Feb. 2021, doi: https://doi.org/10.1007/s00109-021-02045-7.
[13] Kumar, A.S. “Stem Cell Therapeutics for Crohn’s Disease - NHSJS.” NHSJS. 2025 Available at: https://nhsjs.com/2025/stem-cell-therapeutics-for-crohns-disease/.
Downloads
Published
License
Copyright (c) 2025 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
